Pat Gage has enjoyed various positions of leadership in the pharmaceutical and biotech industry including as President of Wyeth Research and also of Genetics Institute. He began his career at Hoffmann-La Roche and advanced from the Institute of Molecular Biology to V.P., Exploratory Research (Discovery Research for the US). In 1989, he joined Genetics Institute, Inc first as R&D head, and then President in 1997 after Wyeth [now Pfizer] acquired the company. Dr. Gage was then named President of Wyeth Research, taking responsibility for global pharmaceutical and vaccine R&D of Wyeth and Genetics Institute, and then was also named SVP, Science and Technology for Wyeth. During his career at Roche, GI and Wyeth, he oversaw the development of more than a dozen marketed biologics, both protein pharmaceuticals and vaccines, as well as several small molecule drugs.

Dr. Gage currently serves as Chairman of Cytokinetics [CYTK] and also of Tetraphase Pharmaceuticals, and is a member of the boards of three other private biotech companies, Alvine Pharmaceuticals, Corridor Pharmaceuticals and Permeon Biologics. He is also Chair of the advisory board for biologics research at Merck, and a member of the SABs for Pappas Ventures and aTyr Pharma. In the past, Dr. Gage has served as a Venture Partner at Flagship Ventures, and on several other industry boards. In addition, Pat is a Trustee of the Marine Biological Laboratories, Woods Hole, MA and the Wistar Institute, Philadelphia, and was the Founding Chairman of Molecular Medicine Ireland.

Dr. Gage holds a bachelor’s degree in Physics from the Massachusetts Institute of Technology, and a doctorate in Biophysics from the University of Chicago.